131 related articles for article (PubMed ID: 36221995)
1. Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy.
Márquez-Algaba E; Iacoboni G; Pernas B; Esperalba J; Los Arcos I; Navarro V; Monforte A; Beas F; Albasanz-Puig A; Carpio C; Barba P; Ruiz-Camps I
Transplant Cell Ther; 2022 Dec; 28(12):851.e1-851.e8. PubMed ID: 36221995
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Kampouri E; Ibrahimi SS; Xie H; Wong ER; Hecht JB; Sekhon MK; Vo A; Stevens-Ayers TL; Green DJ; Gauthier J; Maloney DG; Perez A; Jerome KR; Leisenring WM; Boeckh MJ; Hill JA
Clin Infect Dis; 2024 Apr; 78(4):1022-1032. PubMed ID: 37975819
[TBL] [Abstract][Full Text] [Related]
3. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
5. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
Mariotti J; Maura F; Spina F; Roncari L; Dodero A; Farina L; Montefusco V; Carniti C; Sarina B; Patriarca F; Rambaldi A; Onida F; Olivieri A; Zallio F; Corradini P
Biol Blood Marrow Transplant; 2014 Jun; 20(6):885-90. PubMed ID: 24583412
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study.
Fernández-García OA; García-Juárez I; Belaunzarán-Zamudio PF; Vilatoba M; Wisniowski-Yáñez A; Salomón-Ávila J; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Cuellar-Rodríguez JM
BMC Infect Dis; 2022 Feb; 22(1):155. PubMed ID: 35164684
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?
Solano de la Asunción C; Hernani R; Albert E; Gómez MD; Giménez E; Benzaquén A; González-Barberá EM; Hernández-Boluda JC; Pérez A; Piñana JL; Chorao P; Guerreiro M; Montoro J; Sanz J; Solano C; Navarro D
Clin Microbiol Infect; 2023 Aug; 29(8):1093-1095. PubMed ID: 37182642
[No Abstract] [Full Text] [Related]
8. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
9. Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: A rare but potentially fatal complication.
Cousin E; Belicard F; Michel L; Pronier C; Lassalle N; Lamy T; Houot R; Lhomme F
J Med Virol; 2021 Nov; 93(11):6398-6403. PubMed ID: 34370316
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
11. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up.
Cheng J; Huang J; Cao W; Huang L; Mao X; Chen L; Zhou J; Wang N
Front Immunol; 2023; 14():1226148. PubMed ID: 37849765
[TBL] [Abstract][Full Text] [Related]
13. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
[TBL] [Abstract][Full Text] [Related]
14. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
16. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
17. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
18. Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies.
Huntley D; Talaya A; Giménez E; Martínez A; Hernández-Boluda JC; Hernani R; Torres I; Alberola J; Albert E; Piñana JL; Solano C; Navarro D
Biol Blood Marrow Transplant; 2020 May; 26(5):972-977. PubMed ID: 32007638
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells.
Beyar-Katz O; Kikozashvili N; Bar On Y; Amit O; Perry C; Avivi I; Gold R; Herishanu Y; Benyamini N; Duek A; Ben-Ami R; Shasha D; Ram R
Eur J Haematol; 2022 Jan; 108(1):52-60. PubMed ID: 34564876
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.
Huang YT; Su Y; Kim SJ; Nichols P; Burack D; Maloy M; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2019 Apr; 25(4):791-799. PubMed ID: 30476551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
